Cotadutide对糖尿病肾病患者肾脏结局的2b期随机试验
这项2b期随机试验纳入248例2型糖尿病合并慢性肾脏病患者,评估GLP-1/胰高血糖素受体激动剂cotadutide对尿白蛋白/肌酐比值(UACR)的影响。结果显示cotadutide 300 μg和600 μg在14周时显著降低UACR,且耐受性可接受,提示其可能具有肾脏保护作用,但需更大规模研究确认。
要点
- Cotadutide 300 μg和600 μg在14周时显著降低UACR,降幅分别为43.9%和49.9%。
- 降UACR效应在26周时仍持续,严重不良事件在各组间均衡。
- Cotadutide 600 μg安全性与司美格鲁肽1 mg可比,需更大规模研究确认肾脏保护获益。
核心结论
- 在2型糖尿病合并慢性肾脏病患者中,cotadutide在标准治疗基础上显著降低UACR且耐受性可接受,提示肾脏保护获益需更大规模研究确认。
研究设计与样本
- 2b期随机、双盲、安慰剂对照试验,248例2型糖尿病合并慢性肾脏病患者按1:1:1:1:1随机分配。
- 患者接受标准治疗加皮下cotadutide每日上调至100、300或600 μg,或安慰剂(双盲),或司美格鲁肽1 mg每周一次(开放标签),治疗26周。
- 共同主要终点为第14周末UACR相对基线的绝对变化和百分比变化(对比安慰剂)。
主要发现
- 第14周末,cotadutide 300 μg组UACR较安慰剂降低43.9%(95%CI -54.7至-30.6),600 μg组降低49.9%(95%CI -59.3至-38.4)。
- cotadutide降低UACR呈剂量依赖性,效应持续至第26周。
- 严重不良事件在各组间均衡,cotadutide 600 μg安全性和耐受性与司美格鲁肽1 mg可比。
关键数值与推荐
- 入选标准:估算肾小球滤过率(eGFR)≥20且<90 mL/min/1.73 m2,尿白蛋白/肌酐比值(UACR)>50 mg/g。
- 248例随机患者平均年龄67.1岁,女性占19%,平均eGFR 55.3 mL/min/1.73 m2,UACR几何均值205.5 mg/g(变异系数270.0),46.8%合并使用钠-葡萄糖共转运蛋白2抑制剂。
临床怎么用
- 对于2型糖尿病合并慢性肾脏病患者,cotadutide在标准治疗基础上可显著降低UACR,且耐受性可接受。
- cotadutide 600 μg的安全性与司美格鲁肽1 mg可比,但肾脏保护获益需更大规模研究确认。
局限性
- 研究为2b期试验,样本量有限,肾脏保护获益需更大规模研究确认。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Cotadutide is a glucagon-like peptide-1 (GLP-1) and glucagon receptor agonist that may improve kidney function in patients with type 2 diabetes (T2D) and chronic kidney disease (CKD). In this phase 2b study, patients with T2D and CKD (estimated glomerular filtration rate [eGFR] of 20 or more and under 90 mL/min per 1.73 m2 and urinary albumin-to-creatinine ratio [UACR] over 50 mg/g) were randomized 1:1:1:1:1 to 26 weeks' treatment with standard of care plus subcutaneous cotadutide uptitrated to 100, 300, or 600 μg, or placebo daily (double-blind), or the GLP-1 agonist semaglutide 1 mg once weekly (open-label).The co-primary endpoints were absolute and percentage change versus placebo in UACR from baseline to the end of week 14. Among 248 randomized patients, mean age 67.1 years, 19% were female, mean eGFR was 55.3 mL/min per 1.73 m2, geometric mean was UACR 205.5 mg/g (coefficient of variation 270.0), and 46.8% were receiving concomitant sodium-glucose co-transporter 2 inhibitors. Cotadutide dose-dependently reduced UACR from baseline to the end of week 14, reaching significance at 300 μg (-43.9% [95% confidence interval -54.7 to -30.6]) and 600 μg (-49.9% [-59.3 to -38.4]) versus placebo; with effects sustained at week 26. Serious adverse events were balanced across arms. Safety and tolerability of cotadutide 600 μg were comparable to semaglutide. Thus, our study shows that in patients with T2D and CKD, cotadutide significantly reduced UACR on top of standard of care with an acceptable tolerability profile, suggesting kidney protective benefits that need confirmation in a larger study.
引用
- Selvarajah V, Robertson D, Hansen L, et al. A randomized phase 2b trial examined the effects of the glucagon-like peptide-1 and glucagon receptor agonist cotadutide on kidney outcomes in patients with diabetic kidney disease. Kidney Int. 2024. PMID: 39218393. doi:10.1016/j.kint.2024.08.023
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。